<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107051</url>
  </required_header>
  <id_info>
    <org_study_id>339-101-00015</org_study_id>
    <nct_id>NCT04107051</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients With Alcohol Dependence</brief_title>
  <official_title>Nalmefene Hydrochloride Hydrate Tablets 10mg Specified Drug-use Results Survey (the Safety and the Prognosis After Achieving Reduced Alcohol Intake)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and the prognosis after achieving
      reduced alcohol intake in patients with alcohol dependence who received treatment for the
      reduction of alcohol intake in the routine clinical setting in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Use Disorders Identification Test-Consumption(AUDIT-C)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Alcohol Dependence</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene Hydrochloride Hydrate</intervention_name>
    <description>Oral administration of nalmefene hydrochloride hydrate</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with alcohol dependence who are planned to be newly started on nalmefene
        hydrochloride hydrate for the treatment of reduction of alcohol consumption.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Alcohol Dependence

          -  Must agree to follow-up during the first year of prescription and publication of
             survey results

          -  Patients whose goal of treatment for Alcohol Dependence is to reduce alcohol
             consumption

          -  Patients receiving psychosocial treatment aiming to promote treatment adherence and
             reduction of alcohol consumption

          -  Patients who have chronic heavy drinking

          -  Patients who have confirmed that they are willing to receive treatment to reduce their
             alcohol consumption

        Exclusion Criteria:

          -  Patients who has ever been treated with nalmefene hydrochloride hydrate

          -  Patients who are contraindicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasuhiko Fukuta, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd.</last_name>
    <phone>+81-6-6942-7396</phone>
    <email>Sugimoto.Yuna@otsuka.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Otsuka Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pharmacovigilance Department</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalmefene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

